Abstract
A molecular scaffold bearing eight terminal alkyne groups was synthesized from sucrose. Eight copies of an azide-terminated, azo-linked precursor to 5-aminosalicylic acid were attached to the scaffold via copper(I)-catalyzed azide-alkyne cycloaddition. The resulting compound was evaluated in a DSS model of colitis in BALB/c mice against sulfasalazine as a control. Two independent studies verified that the novel pro-drug, administered in a dose calculated to result in an equimolar 5-ASA yield, outperformed sulfasalazine in terms of protection from mucosal inflammation and T cell activation. A separate study established that 5-ASA appeared in feces produced 24-48 h following administration of the pro-drug. Thus, a new, orally administered pro-drug form of 5-aminosalicylic acid has been developed and successfully demonstrated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 710-714 |
| Number of pages | 5 |
| Journal | ACS Medicinal Chemistry Letters |
| Volume | 3 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 13 2012 |
Keywords
- 5-aminosalicylic acid
- Inflammatory bowel disease
- pro-drug
ASJC Scopus subject areas
- Biochemistry
- Drug Discovery
- Organic Chemistry
Fingerprint
Dive into the research topics of 'Design, synthesis, and testing of a molecular truck for colonic delivery of 5-aminosalicylic acid'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS